RARE CANCER CELL DETECTION METHOD

罕见癌细胞检测方法

• 批准号: 6344501
• 负责人: JAN TRNOVSKY
• 金额: $ 38.05万
• 依托单位: ONE CELL SYSTEMS, INC
• 依托单位国家: 美国
• 财政年份: 2000
• 资助国家: 美国
• 起止时间: 2000-05-01 至 2004-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6344501
• 关键词: biomarker; cytodiagnosis; diagnosis design /evaluation; early diagnosis; enzyme activity; flow cytometry; fluorescent in situ hybridization; gel; human tissue; method development; neoplasm /cancer diagnosis; neoplastic cell; surface property; telomerase

Fluorescence in situ hybridization (FISH) assays are increasingly used to identify chromosomal translocations, duplications, deletions, and other chromosomal abnormalities associated with specific cancers. However, current assay formats rely on manual and labor intensive microscopic examination making rare cell detection impractical. For early diagnosis of leukemias and for detecting therapeutic relapse, sensitive, high throughput assays which can detect one cancer cell in the presence of at least 1,000 non-cancerous cells are needed. By combining gel microdrop single cell encapsulation (GMD) technology, fluorescence in situ hybridization (FISH), and flow cytometry, we have developed an assay to detect telomerase mRNA (tmRNA), which is a potentially valuable marker for early cancer detection because carcinogenesis is dependent on telomerase activation. Using clinical samples, Phase I research will identify cancer cells in human blood for early diagnosis of chronic leukemias. PROPOSED COMMERCIAL APPLICATIONS: The assay will permit early and accurate diagnosis of cancer, facilitating early treatment and reducing mortality rates. The assay will also permit monitoring of the effectiveness of the clinical treatment, facilitating development of new therapeutics and cancer treatments.

越来越多地使用荧光原位杂交（FISH）测定法来鉴定与特定癌症相关的染色体易位，重复，缺失和其他染色体异常。但是，当前的测定格式依赖于手动和劳动密集型显微镜检查，这使得罕见的细胞检测不切实际。为了早期诊断白血病和检测治疗性复发，敏感的高吞吐量测定方法，可以在至少1,000个非癌细胞的情况下检测一个癌细胞。通过将凝胶微螺旋头单细胞包装（GMD）技术，荧光原位杂交（FISH）和流式细胞术结合，我们开发了一种检测端粒酶mRNA（TMRNA）的测定法，这是一种潜在的早期癌症检测标记物，因为癌变依赖于远程触发型。使用临床样品，I期研究将鉴定人类血液中的癌细胞以早期诊断慢性白血病。拟议的商业应用：该测定法将允许对癌症进行早期和准确的诊断，促进早期治疗并降低死亡率。该测定法还将允许监测临床治疗的有效性，促进新的治疗剂和癌症治疗的发展。